{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-033870","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2024-08-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.703750+00:00","generated_at":"2026-05-31T07:35:51.798163+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lixte dosed first patient with LB-100 in new colorectal cancer trial with NKI and Roche support","bullets":["Dosed first patient in clinical trial NCT06012734 for MSI Low metastatic colorectal cancer.","Trial collaboration with Netherlands Cancer Institute (NKI); Roche supplies atezolizumab (Tecentriq).","Second pharma-funded LB-100 immunotherapy trial; earlier GSK trial for clear cell ovarian cancer started 2024.","Aims to bring immunotherapy to ~85% of colorectal cancer patients currently unresponsive."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-033870","json":"https://secwatch.observer/filing/0001493152-24-033870.json","markdown":"https://secwatch.observer/filing/0001493152-24-033870.md","text":"https://secwatch.observer/filing/0001493152-24-033870.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315224033870/0001493152-24-033870-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315224033870/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:35:51.798163+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}